Loading…
AMOXICILLIN/CLAV is a brand name for Amoxicillin, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AMOXICILLIN/CLAV (Amoxicillin and Clavulanate potassium tablets) is indicated for the treatment of the following infections when caused by AMOXICILLIN/CLAV susceptible strains of the designated bacteria: • Sinusitis when caused by β-lactamase producing strains of H. influenzae or Moraxella (Branhamella) catarrhalis. •…
Verbatim from this product's HC label. Tap a section to expand.
2 Recommended Dose and Dosage Adjustment Adults For mild to moderate infections, the usual adult dose is one AMOXICILLIN/CLAV (500 mg amoxicillin / 125 mg clavulanic acid) tablet every 12 hours. For more severe infections (including chronic and recurrent urinary tract infections and infections of the lower respiratory tract), the dose should be one AMOXICILLIN/CLAV (875 mg amoxicillin / 125 mg clavulanic acid) every 12 hours or one AMOXICILLIN/CLAV (500 mg amoxicillin / 125 mg clavulanic acid) every 8 hours.
Children weighing more than 38 kg should be dosed according to adult recommendations. Renal Insufficiency Dosage adjustment in renal impairment is based on the maximum recommended level of amoxicillin. e. 875 mg amoxicillin / 125 mg clavulanic acid) should be used only in patients with a creatinine clearance of more than 30 mL/min.
Adults AMOXICILLIN/CLAV Product Monograph Page 6 of 37 Creatinine clearance > 30 mL/min No adjustment necessary. Creatinine clearance 10 - 30 mL/min 500 mg / 125 mg tablet given twice daily. Creatinine clearance < 10 mL/min 500 mg / 125 mg tablet given once daily.
Hemodialysis One 500 mg / 125 mg tablet every 24 h, PLUS one 500 mg / 125 mg tablet during dialysis, to be repeated at the end of dialysis (as serum concentrations of both amoxicillin and clavulanic acid are decreased). 875 mg / 125 mg tablets (7:1 ratio of amoxicillin:clavulanate) should only be used in patients with a creatinine clearance of more than 30 ml/min.
4 Administration While AMOXICILLIN/CLAV can be given without regard to meals, absorption of clavulanic acid when taken with food is greater relative to the fasted state. Dosing in the fasted or fed state has minimal effect on the pharmacokinetics of amoxicillin.
The safety and efficacy of amoxicillin / clavulanate potassium have been established in clinical trials where amoxicillin / clavulanate potassium was taken without regard to meals. To minimize potential gastrointestinal intolerance, administer at the start of a meal.
5 Missed Dose If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose. The dose should not be doubled to make up for a missed dose.
). Cardiovascular Abnormal prolongation of prothrombin time (increased international normalized ratio (INR)) has been reported in patients receiving amoxicillin / clavulanate potassium and oral anticoagulants. Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently.
Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation. Kounis syndrome (see 7 WARNINGS AND PRECAUTIONS, Hypersensitivity Reactions). AMOXICILLIN/CLAV Product Monograph Page 9 of 37 Hepatic/Biliary/Pancreatic Transient hepatitis and cholestatic jaundice have been reported rarely.
These events have been noted with other penicillins and cephalosporins. Hepatic injury events associated with AMOXICILLIN/CLAV may be severe, and occur predominantly in males and elderly patients and may be associated with prolonged treatment.
These events have been very rarely reported in children. Signs and symptoms usually occur during or shortly after treatment, but in some cases may not become apparent until several weeks after treatment has ceased. Hepatic toxicity associated with the use of amoxicillin / clavulanate potassium is usually reversible.
On rare occasions, deaths have been reported (less than 1 death reported per estimated 4 million prescriptions worldwide). 5 Post-Market Adverse Reactions, Liver). AMOXICILLIN/CLAV should be used with caution in patients with evidence of hepatic dysfunction.
, acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS). These have been reported in patients on penicillin therapy, including amoxicillin / clavulanate potassium.
• Kounis syndrome, a serious allergic reaction that can result in myocardial infarction. Presenting symptoms of such reactions can include chest pain occurring in association with an allergic reaction to amoxicillin-clavulanate. • Drug-induced enterocolitis syndrome, an allergic reaction with the leading symptom of protracted vomiting (1-4 hours after medicinal product administration), in the absence of allergic skin or respiratory symptoms, has been reported mainly in children receiving amoxicillin-clavulanate.
, Immune 08/2024 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ...............................................................................................
2 TABLE OF CONTENTS ................................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION .........................................................................
4 1 INDICATIONS...................................................................................................................... 1 Pediatrics .....................................................................................................................
2 Geriatrics ..................................................................................................................... 4 2 CONTRAINDICATIONS ........................................................................................................
5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................................... 5 4 DOSAGE AND ADMINISTRATION ........................................................................................ 2 Recommended Dose and Dosage Adjustment ............................................................
4 Administration............................................................................................................. 5 Missed Dose ................................................................................................................
6 5 OVERDOSAGE .................................................................................................................... 6 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ........................................ 7 7 WARNINGS AND PRECAUTIONS .........................................................................................
AMOXICILLIN/CLAV is contraindicated in patients: • with a history of hypersensitivity to the penicillin, or cephalosporin group of β-lactams, or to any ingredients contained in the preparation or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
• where infectious mononucleosis is either suspected or confirmed. • with a previous history of AMOXICILLIN/CLAV associated jaundice/hepatic dysfunction.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Amoxicillin in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Further symptoms could comprise abdominal pain, lethargy, diarrhea, hypotension or leucocytosis with neutrophilia. In severe cases, drug-induced enterocolitis syndrome can progress to shock. 5 Post-Market Adverse Reactions) Although these reactions are more frequent following parenteral therapy, they have occurred in patients receiving penicillins orally.
These reactions are more apt to occur in individuals with a history of sensitivity to multiple allergens. There have been reports of individuals with a history of cephalosporin hypersensitivity who have experienced severe reactions when treated with penicillins.
Before initiating therapy with AMOXICILLIN/CLAV, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens AMOXICILLIN/CLAV Product Monograph Page 10 of 37 (see 2 CONTRAINDICATIONS).
If an allergic reaction occurs, the administration of AMOXICILLIN/CLAV should be discontinued and appropriate alternative therapy should be instituted. Serious anaphylactic/anaphylactoid reactions require immediate emergency treatment with epinephrine.
Oxygen, intravenous steroids and airway management, including intubation should also be used as indicated. Monitoring and Laboratory Tests Periodic assessment of renal, hepatic, and hematopoietic function should be made during prolonged therapy with AMOXICILLIN/CLAV.
Renal AMOXICILLIN/CLAV is excreted mostly by the kidney. 2 Recommended Dose and Dosage Adjustment, Renal Insufficiency). In patients with reduced urine output, crystalluria has been observed very rarely, predominantly with parenteral therapy.
During the administration of high doses of amoxicillin, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxicillin crystalluria (see 5 OVERDOSAGE). Sensitivity/Resistance Prescribing AMOXICILLIN/CLAV in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and risks the development of drug-resistant bacteria.
Skin Severe cutaneous adverse reactions (SCAR) have been reported with amoxicillin / potassium clavulanate (see 7 WARNINGS and PRECAUTIONS, Hypersensitivity Reactions). 1 Pregnant Women In a single study in women with preterm, premature rupture of the fetal membranes (pPROM), it was reported that prophylactic treatment with amoxicillin / clavulanate potassium may be associated with an increased risk of necrotizing enterocolitis in neonates.
Use should be avoided in pregnancy, unless considered essential by the physician. 2 Breast-feeding Penicillins (including ampicillin) have been shown to be excreted in human breast milk. It is not known whether clavulanic acid is excreted in breast milk.
Caution should be exercised if AMOXICILLIN/CLAV is to be administered to a nursing mother. 3 Pediatrics No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 2 Clinical Trial Adverse Reactions Clinical trials are conducted under very specific conditions.
The adverse reaction rates observed in the clinical trials; therefore, […]
1 Special Populations ................................................................................................... 1 Pregnant Women ..................................................................................................
2 Breast-feeding ....................................................................................................... 3 Pediatrics ...............................................................................................................
2 Clinical Trial Adverse Reactions ................................................................................. 1 Clinical Trial Adverse Reactions - Pediatrics........................................................... 5 Post-Market Adverse Reactions ................................................................................
4 Drug-Drug Interactions .............................................................................................. 5 Drug-Food Interactions..............................................................................................
6 Drug-Herb Interactions.............................................................................................. 7 Drug-Laboratory Test Interactions ............................................................................ 1 Mechanism of Action.................................................................................................
3 Pharmacokinetics ...................................................................................................... 2 Comparative Bioavailability Studies ..............................................................................
32 AMOXICILLIN/CLAV Product Monograph Page 4 of 37 PART I: HEALTH PROFESSIONAL INFORMATION 1 INDICATIONS AMOXICILLIN/CLAV (Amoxicillin and Clavulanate potassium tablets) is indicated for the treatment of the following infections when caused by AMOXICILLIN/CLAV susceptible strains of the designated bacteria: • Sinusitis when caused by β-lactamase producing strains of H.
influenzae or Moraxella (Branhamella) catarrhalis. • Otitis Media when caused by β-lactamase producing strains of H. influenzae or Moraxella (Branhamella) catarrhalis. • Lower Respiratory Tract Infections when caused by β-lactamase producing strains of H.
influenzae, K. pneumoniae, S. aureus or Moraxella (Branhamella) catarrhalis. • Skin and Soft Tissue Infections when caused by β-lactamase producing strains of S. aureus. • […]